Published in J Cell Sci on January 01, 1992
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol (2000) 3.12
Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A (1997) 2.90
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res (1992) 2.07
Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J (1994) 2.02
Expression of the ERBB3 gene product in breast cancer. Br J Cancer (1992) 2.01
Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol Cell Biol (1999) 1.94
Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol (1993) 1.80
Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome. Biochem J (2002) 1.80
Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol (2002) 1.68
Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol (1994) 1.59
Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet (1999) 1.57
p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle (2010) 1.51
p53 alteration in gastric precancerous lesions. Am J Pathol (1994) 1.45
Defective neurogenesis resulting from DNA ligase IV deficiency requires Atm. Genes Dev (2000) 1.43
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer (1995) 1.40
Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol (1994) 1.39
Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J (1998) 1.39
Involvement of the DNA repair protein hHR23 in p53 degradation. Mol Cell Biol (2003) 1.38
Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer (1994) 1.37
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ (2010) 1.36
Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J (1995) 1.34
Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane. J Cell Biol (2002) 1.27
Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol (1993) 1.25
Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. Mol Cell Biol (1998) 1.19
Role of tumor suppressor p53 domains in selective binding to supercoiled DNA. Nucleic Acids Res (2002) 1.12
Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol (1996) 1.12
Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol (2002) 1.11
p53 mutations in cervical carcinogenesis--low frequency and lack of correlation with human papillomavirus status. Br J Cancer (1994) 1.11
A direct effect of activated human p53 on nuclear DNA replication. EMBO J (1995) 1.10
The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. J Virol (1994) 1.06
The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer (1994) 1.04
Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J Cancer (1993) 1.04
Human cytomegalovirus mtrII oncoprotein binds to p53 and down-regulates p53-activated transcription. J Virol (1996) 1.03
p53 protein in odontogenic cysts: increased expression in some odontogenic keratocysts. J Clin Pathol (1992) 1.02
Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer (1994) 1.01
Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol (1993) 0.99
Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut (1994) 0.99
Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer (1994) 0.98
Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol (1993) 0.98
Ganglioglioma: a detailed histopathological and immunohistochemical analysis of 61 cases. Acta Neuropathol (1994) 0.97
Immunohistochemical analysis of p53 expression in anal squamous neoplasia. J Clin Pathol (1993) 0.96
Chronology of p53 protein accumulation in gastric carcinogenesis. Gut (1995) 0.95
The mannitol repressor (MtlR) of Escherichia coli. J Bacteriol (1994) 0.94
Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer (1992) 0.92
A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Br J Cancer (1996) 0.91
Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma. Thorax (1996) 0.90
Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2. Biochem J (2004) 0.90
Germ cell tumors of the testis overexpress wild-type p53. Am J Pathol (1996) 0.88
Prognostic markers for colorectal cancer: expression of P53 and BCL2. World J Surg (1997) 0.87
Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer (1996) 0.86
p53 expression in dyskeratosis congenita: a marker for oral premalignancy? J Clin Pathol (1993) 0.86
Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer (1995) 0.86
Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ. Br J Cancer (1996) 0.86
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen. Cell Cycle (2008) 0.85
Analysis of chromosome 17p13 (p53 locus) alterations in gastric carcinoma cells by dual-color fluorescence in situ hybridization. Am J Pathol (1996) 0.84
Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells. PLoS One (2013) 0.84
Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings. J Cancer Res Clin Oncol (1997) 0.83
Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining. J Med Genet (1995) 0.83
Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br J Cancer (1995) 0.83
p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer (1994) 0.83
Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer (1998) 0.82
High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br J Cancer (1997) 0.81
p53 expression in lymphatic malignancies. J Clin Pathol (1992) 0.80
Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease. Proc Natl Acad Sci U S A (1993) 0.80
Midgut Carcinoids and Solid Carcinomas of the Intestine: Differences in Endocrine Markers and p53 Mutations. Endocr Pathol (1996) 0.80
Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. J Cancer Res Clin Oncol (1997) 0.80
p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer (1993) 0.79
Mutant p53 protein expression and antioxidant status deficiency in breast cancer. EXCLI J (2014) 0.79
Cancer-specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis. EMBO Rep (2016) 0.77
Cancer-associated S100P protein binds and inactivates p53, permits therapy-induced senescence and supports chemoresistance. Oncotarget (2016) 0.77
Abnormal expression and mutation of p53 in cervical cancer--a study at protein, RNA and DNA levels. Genitourin Med (1997) 0.77
Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors. Horm Cancer (2013) 0.77
p53 protein is absent from the serum of patients with lung cancer. Br J Cancer (1996) 0.77
Proliferative (MIB1, mdm2) Versus Anti-Proliferative (p53) Markers in Head and Neck Cancer. An Immunohistochemical Study. Pathol Oncol Res (1996) 0.76
5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2. Bioorg Med Chem (2013) 0.75
Identification of p53 and its isoforms in human breast carcinoma cells. ScientificWorldJournal (2014) 0.75
p53 mutation and expression in lymphoma. Br J Cancer (1995) 0.75
p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells. Gut (1996) 0.75
A Genetically Encoded Allysine for the Synthesis of Proteins with Site-Specific Lysine Dimethylation. Angew Chem Int Ed Engl (2016) 0.75
Proliferating cell nuclear antigen staining as a prognostic indicator in soft-tissue malignant fibrous histiocytoma. Arch Orthop Trauma Surg (1995) 0.75
Surfing the p53 network. Nature (2000) 35.36
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med (1991) 9.99
STRAND SEPARATION AND SPECIFIC RECOMBINATION IN DEOXYRIBONUCLEIC ACIDS: BIOLOGICAL STUDIES. Proc Natl Acad Sci U S A (1960) 7.50
Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol (1990) 5.90
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer (1983) 4.33
A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med (1987) 3.89
Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med (1995) 3.74
Characteristics of an SV40-plasmid recombinant and its movement into and out of the genome of a murine cell. Cell (1980) 3.66
Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med (1989) 3.41
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods (1992) 3.23
Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med (1992) 2.99
Reproductive and neonatal losses associated with possible encephalomyocarditis virus infection in pigs. Vet Rec (1990) 2.52
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene (1991) 2.42
Antineutrophil cytoplasmic antibodies, cystic fibrosis, and infection. Lancet (1991) 2.41
Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol (2000) 2.35
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol (1993) 2.27
Molecular recognition and the future of monoclonal antibodies. Nature (1982) 2.22
Molecular basis of maternal inheritance. Proc Natl Acad Sci U S A (1972) 2.11
Keratin antigens in differentiating skin. Ann N Y Acad Sci (1985) 2.10
The Birmingham Rehabilitation Uptake Maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation. Heart (2008) 2.03
Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J (1994) 2.02
Expression of the ERBB3 gene product in breast cancer. Br J Cancer (1992) 2.01
Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res (1995) 1.96
The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res (1992) 1.96
Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol Cell Biol (1999) 1.94
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol (1990) 1.94
Cellular proteins reactive with monoclonal antibodies directed against simian virus 40 T-antigen. J Virol (1982) 1.90
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A (1997) 1.81
Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med (2000) 1.70
Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene (1990) 1.69
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer (1990) 1.69
Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res (2000) 1.63
Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol (2000) 1.62
D protein of miniF plasmid acts as a repressor of transcription and as a site-specific resolvase. Nucleic Acids Res (1986) 1.60
Second EcoRI fragment of F capable of self-replication. J Bacteriol (1979) 1.59
Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci (1995) 1.57
Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet (1984) 1.56
Towards a phylogeny of the genus Vibrio based on 16S rRNA sequences. Int J Syst Bacteriol (1992) 1.56
New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet (1997) 1.55
Two methods for measurement of oestradiol-17 beta and progesterone receptors in human breast cancer and correlation with response treatment. Eur J Cancer (1977) 1.52
Multiple tissue core arrays in histopathology research: a validation study. J Pathol (2000) 1.51
Lead toxicosis in mallard ducks. Wildl Dis (1968) 1.46
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
Steroid receptors in human meningioma. Clin Neuropharmacol (1984) 1.45
Pathologic changes in edema disease of swine. Am J Vet Res (1969) 1.43
Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest (1987) 1.43
Severe recalcitrant erythematous desquamating disorder associated with fatal recurrent toxic shock syndrome in a patient without AIDS. Clin Infect Dis (1997) 1.40
The Birmingham Rehabilitation Uptake Maximisation Study (BRUM). Home-based compared with hospital-based cardiac rehabilitation in a multi-ethnic population: cost-effectiveness and patient adherence. Health Technol Assess (2007) 1.39
Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer (1994) 1.37
Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer (2003) 1.37
Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer (1993) 1.36
Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol Carcinog (1991) 1.33
Coordinate expression of the endogenous p53 gene in beta cells of transgenic mice expressing hybrid insulin-SV40 T antigen genes. EMBO J (1987) 1.32
Feline mammary hypertrophy/fibroadenoma complex: clinical and hormonal aspects. Am J Vet Res (1981) 1.30
p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem (2001) 1.30
Underusers of mammogram screening: stage of adoption in five U.S. subpopulations. The NCI Breast Cancer Screening Consortium. Prev Med (1998) 1.28
Why do doctors find some patients difficult to help? Q J Med (1994) 1.28
Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene (1998) 1.28
Enlarged family of putative helicases. Nature (1988) 1.27
Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer (1998) 1.27
Measurement of oestradiol receptors by five institutions on common tissue samples. Br J Cancer (1978) 1.26
The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer (1985) 1.26
The Rapid Acute Physiology Score. Am J Emerg Med (1987) 1.24
KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma. J Pathol (1992) 1.23
Neoplasms of the canine and feline urinary bladder: incidence, etiologic factors, occurrence and pathologic features. Am J Vet Res (1968) 1.22
DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer (1990) 1.21
Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component. Semin Diagn Pathol (1994) 1.21
Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene (1997) 1.19
Mapping of the drug resistance genes carried by the r-determinant of the R100.1 plasmid. Mol Gen Genet (1977) 1.19
A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage. Br J Cancer (1995) 1.17
Development of bilirubin transport and metabolism in the newborn rhesus monkey. J Pediatr (1977) 1.16
Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol (2001) 1.16
Cellular localization and T antigen binding of the retinoblastoma protein. Oncogene (1992) 1.16
Awakening angels. Nature (1998) 1.15
Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene (1991) 1.15
Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. Histochem J (1986) 1.15
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer (1999) 1.14
The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. JAMA (1993) 1.14
Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol (1993) 1.13
Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology (1993) 1.13
Properties of an autonomous r-determinant from R100.1. Cold Spring Harb Symp Quant Biol (1979) 1.13
Q-beta replicase-amplified assay for detection of Mycobacterium tuberculosis directly from clinical specimens. J Clin Microbiol (1995) 1.12
Forecasting demand for long-term care services. Health Serv Res (1985) 1.12
Expression of the second lysine decarboxylase gene of Escherichia coli. Microbiology (1998) 1.11
Regulation of human alveolar macrophage inflammatory cytokine production by interleukin-10. Clin Immunol Immunopathol (1996) 1.10
Grim projections for AIDS epidemic. Science (1986) 1.10
c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene (2006) 1.09
Apoptosis, ageing and cancer susceptibility. Br J Cancer (2003) 1.08
Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur J Cancer (1990) 1.08
Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol (1990) 1.08
Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer (1992) 1.07
Role of the ATP-binding site of SopA protein in partition of the F plasmid. J Mol Biol (2001) 1.07